MediWound develops enzyme-based therapies that remove damaged tissue from burns and chronic wounds. It last closed at $13.68 on Nov 17, up 0.96% on the day. MDWD last reported earnings on Wed, May 27, 2026.
From MDWD's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 5). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
MDWD · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend
The stock is 3% above its 20 day and 3% above its 50 day average. It is 10% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 54). The nearest support is the Pivot at $13.62, and the nearest resistance the swing high (Oct 29) at $13.99.
Short trendBullish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 5.0%/day
Key levels
$19.7052 week high+44.0%
$15.00200 day average+9.6%
$14.01Pivot R1+2.4%
$13.99Swing high (Oct 29)+2.3%
$13.68Last close
$13.62Pivot−0.4%
$13.59100 day average−0.7%
$13.54Swing low (Jun 2)−1.0%
$13.30Pivot S1−2.8%
$13.2720 day average−3.0%
$13.2150 day average−3.4%
$11.8052 week low−13.7%
Indicators
RSI (14)
53.79
Middle of its range
Neutral
MACD
0.16
Below its signal line
Bearish
Stochastic
45.5
Middle of its range
Neutral
ADX (14)
19.7
No clear trend
Williams %R
-44.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
45.1
Oversold below −100, overbought above 100
Neutral
Rate of change
+2.2%
Change over 10 sessions
Bullish
ATR (14)
$0.68
Typical daily range, 5.0% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Below
Turning down
Short trendBearish
Long trendNeutral
MomentumImproving
StretchNormal
VolatilityNormal, 9.1%/day
Key levels
$19.7052 week high+44.0%
$15.00200 day average+9.6%
$14.01Pivot R1+2.4%
$13.99Swing high (Oct 29)+2.3%
$13.68Last close
$13.62Pivot−0.4%
$13.59100 day average−0.7%
$13.54Swing low (Jun 2)−1.0%
$13.30Pivot S1−2.8%
$13.2720 day average−3.0%
$13.2150 day average−3.4%
$11.8052 week low−13.7%
Indicators
RSI (14)
48.22
Middle of its range
Neutral
MACD
-0.62
Above its signal line
Bullish
Stochastic
64.5
Middle of its range
Neutral
ADX (14)
22.5
Weak trend
Williams %R
-33.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
-11.4
Oversold below −100, overbought above 100
Neutral
Rate of change
+4.3%
Change over 10 sessions
Bullish
ATR (14)
$1.24
Typical daily range, 9.1% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for MDWD
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MDWD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow MDWD usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How MDWD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MDWD is in one of them and how their past MDWD trades turned out.
MediWound develops enzyme-based therapies that remove damaged tissue from wounds while leaving healthy tissue in place. Its main product, NexoBrid, treats deep burns and is approved in many countries. The company is also developing EscharEx, a topical treatment for chronic wounds such as venous leg ulcers, and a candidate for basal cell carcinoma. It makes its products at its facility in Yavne, Israel, and its customers are hospitals and healthcare providers treating burn and wound patients.